SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Lonza Group AG LZAGF OTC

Other OTC • Healthcare • Medical - Diagnostics & Research • CH • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Lonza Group AG (LZAGF) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $687.12. It has a SharesGrow Score of 65/100, indicating a above average investment profile with 3 out of 7 criteria passed.

Financials: revenue is $6.5B, +1.7%/yr average growth. Net income is $949M, growing at +0.1%/yr. Net profit margin is 14.5% (healthy). Gross margin is 35.4% (-3.8 pp trend).

Balance sheet: total debt is $4.2B against $9.1B equity (Debt-to-Equity (D/E) ratio 0.46, conservative). Current ratio is 2.24 (strong liquidity). Debt-to-assets is 22.1%. Total assets: $19.0B.

Analyst outlook: 1 / 1 analysts rate LZAGF as buy (100%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 15/100 (Fail), Growth 45/100 (Partial), Past 100/100 (Pass), Health 83/100 (Pass), Moat 57/100 (Partial), Future 100/100 (Pass), Income 55/100 (Partial).

LZAGF SharesGrow Score Overview

65/100

SharesGrow Score

Above average fundamentals

View full scorecard →

VALUE 15/100

Valuation — P/E, PEG, Forward PEG

GROWTH 45/100

Financials — average growth

PAST 100/100

strong — trend

HEALTH 83/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 57/100

Gross margin is + market cap

FUTURE 100/100

Analyst outlook — as buy

INCOME 55/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — LZAGF

LZAGF trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

LZAGF: +1.7%/yr revenue is, +0.1%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

LZAGF: 4 / 4 years profitable. strong — 100%. Score = 4 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet LZAGF: Debt-to-Equity (D/E) ratio 0.46 (conservative), Current ratio is 2.24 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

LZAGF: Gross margin is 35.4% (-3.8 pp trend), $48B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 57/100. ≥ 70 = Pass.

View details →

Analyst outlook: 1 / 1 analysts rate LZAGF as buy (100%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.

View details →

LZAGF: Net profit margin is 14.5%. thin (5-15%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range562.23-755.96

Volume143

Avg Volume (30D)848

Market Cap$48.28B

Beta (1Y)0.89

Dividend Yield$7.1424

Share Statistics

EPS (TTM)13.55

Shares Outstanding$70.04M

IPO Date2009-02-13

Employees17,995

CEOWolfgang Wienand

Financial Highlights & Ratios

Revenue (TTM)$6.53B

Gross Profit$2.31B

EBITDA$1.31B

Net Income$949M

Operating Income$1.24B

Total Cash$719M

Total Debt$4.19B

Net Debt$3.47B

Total Assets$18.97B

Price / Earnings (P/E)50.7

Price / Sales (P/S)7.39

Analyst Forecast

Rating ConsensusBuy

Analysts Covering1

Buy 100% Hold 0% Sell 0%

Company Info

CountryCH

ExchangeOther OTC

CurrencyUSD

ISINCH0013841017

Price Chart

LZAGF

Lonza Group AG ↗ · Other OTC

Healthcare • Medical - Diagnostics & Research

562.23 52WK RANGE 755.96

People Also View

Thermo Fisher Scientific Inc.

Danaher Corporation

IDEXX Laboratories, Inc.

Agilent Technologies, Inc.

Waters Corporation

Charles River Laboratories International, Inc.

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message